Roles of histone acetylation sites in cardiac hypertrophy and heart failure

被引：13

作者：

Funamoto, Masafumi ^{[1
]}

Imanishi, Masaki ^{[2
]}

Tsuchiya, Koichiro ^{[2
]}

Ikeda, Yasumasa ^{[1
]}

机构：

[1] Tokushima Univ, Inst Biomed Sci, Dept Pharmacol, Grad Sch, Tokushima, Japan

[2] Tokushima Univ, Inst Biomed Sci, Dept Med Pharmacol, Grad Sch, Tokushima, Japan

来源：

FRONTIERS IN CARDIOVASCULAR MEDICINE | 2023年 / 10卷

关键词：

epigenetics; histone post-translational modification; cardiac hypertrophy; heart failure; acetylation; ACETYLTRANSFERASE ACTIVITY; EPIGENETIC REGULATION; DEACETYLASE; P300; METHYLATION; RESPONSES; COMPLEX; GATA4; ACTS;

D O I：

10.3389/fcvm.2023.1133611

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Heart failure results from various physiological and pathological stimuli that lead to cardiac hypertrophy. This pathological process is common in several cardiovascular diseases and ultimately leads to heart failure. The development of cardiac hypertrophy and heart failure involves reprogramming of gene expression, a process that is highly dependent on epigenetic regulation. Histone acetylation is dynamically regulated by cardiac stress. Histone acetyltransferases play an important role in epigenetic remodeling in cardiac hypertrophy and heart failure. The regulation of histone acetyltransferases serves as a bridge between signal transduction and downstream gene reprogramming. Investigating the changes in histone acetyltransferases and histone modification sites in cardiac hypertrophy and heart failure will provide new therapeutic strategies to treat these diseases. This review summarizes the association of histone acetylation sites and histone acetylases with cardiac hypertrophy and heart failure, with emphasis on histone acetylation sites.

引用

页数：7

共 50 条

[21] Noncoding RNAs in Cardiac Hypertrophy and Heart Failure
Lu, Peilei
Ding, Fan
Xiang, Yang Kevin
Hao, Liying
Zhao, Meimi
CELLS, 2022, 11 (05)
[22] PROTEIN METABOLISM IN CARDIAC HYPERTROPHY + HEART FAILURE
GUDBJARNASON, S
TELERMAN, M
BING, RJ
AMERICAN JOURNAL OF PHYSIOLOGY, 1964, 206 (02): : 294 - &
[23] Statin therapy for cardiac hypertrophy and heart failure
Liao, JK
JOURNAL OF INVESTIGATIVE MEDICINE, 2004, 52 (04) : 248 - 253
[24] Role of MicroRNAs in Cardiac Hypertrophy and Heart Failure
Wang, Nan
Zhou, Zhen
Liao, Xinghua
Zhang, Tongcun
IUBMB LIFE, 2009, 61 (06) : 566 - 571
[25] RNA methylation in cardiac hypertrophy and heart failure
Buchholz, E.
Berulava, T.
Lbik, D.
Sloan, K.
Mohamed, B.
Bohnsack, M.
Hasenfuss, G.
Fischer, A.
Toischer, K.
EUROPEAN HEART JOURNAL, 2018, 39 : 644 - 645
[26] The Cardiac Microvasculature in Hypertension, Cardiac Hypertrophy and Diastolic Heart Failure
Hoenig, Michel R.
Bianchi, Cesario
Rosenzweig, Anthony
Sellke, Frank W.
CURRENT VASCULAR PHARMACOLOGY, 2008, 6 (04) : 292 - 300
[27] Histone Acetylation is Not Required for Reactivation of ANP and BNP in Human Heart Failure
Hohl, Mathias
Mueller, Sarah-Anne
Tauchnitz, Marcus
Zimmer, Angela M.
Ekici, Myriam
Backs, Johannes
Thiel, Gerald
Boehm, Michael
Maack, Christoph
CIRCULATION, 2010, 122 (21)
[28] Histone H3 Globular Domain Acetylation is Promoted by the Interaction of P300 With BRG1 During the Transition From Cardiac Hypertrophy to Heart Failure
Funamoto, Masafumi
Sunagawa, Yoichi
Katanasaka, Yasufumi
Shimizu, Kana
Miyazaki, Yusuke
Sari, Nurmila
Shimizu, Satoshi
Wada, Hiromichi
Hasegawa, Koji
Morimoto, Tatsuya
CIRCULATION, 2018, 138
[29] Novel Pharmacological Therapies for Cardiac Hypertrophy and Heart Failure
Kang, Peter M.
CURRENT PHARMACEUTICAL DESIGN, 2011, 17 (18) : 1773 - 1773
[30] Vitamin D Therapy in Cardiac Hypertrophy and Heart Failure
Wu-Wong, J. Ruth
CURRENT PHARMACEUTICAL DESIGN, 2011, 17 (18) : 1794 - 1807

← 1 2 3 4 5 →